Dag Clement Johannessen
Overview
Explore the profile of Dag Clement Johannessen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
453
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ekanger C, Helle S, Heinrich D, Johannessen D, Karlsdottir A, Nygard Y, et al.
Adv Radiat Oncol
. 2020 Jun;
5(3):396-403.
PMID: 32529133
Purpose: There is no consensus on how to treat high-risk prostate cancer, and long-term results from hypofractionated radiation therapy are lacking. We report 10-year results after image guided, intensity modulated...
2.
Parker C, Coleman R, Sartor O, Vogelzang N, Bottomley D, Heinrich D, et al.
Eur Urol
. 2017 Jul;
73(3):427-435.
PMID: 28705540
Background: In Alpharadin in Symptomatic Prostate Cancer (ALSYMPCA) trial, radium-223 versus placebo prolonged overall survival with favorable safety in castration-resistant prostate cancer patients with symptomatic bone metastases. Long-term radium-223 monitoring...
3.
Hoskin P, Sartor O, OSullivan J, Johannessen D, Helle S, Logue J, et al.
Lancet Oncol
. 2014 Dec;
15(12):1397-406.
PMID: 25439694
Background: Primary results from the phase 3 ALSYMPCA trial showed that radium-223 dichloride (radium-223), a targeted α-emitter, improved overall survival compared with placebo and was well tolerated in patients with...
4.
Sartor O, Coleman R, Nilsson S, Heinrich D, Helle S, OSullivan J, et al.
Lancet Oncol
. 2014 May;
15(7):738-46.
PMID: 24836273
Background: Bone metastases frequently cause skeletal events in patients with metastatic castration-resistant prostate cancer. Radium-223 dichloride (radium-223) selectively targets bone metastases with high-energy, short-range α-particles. We assessed the effect of...
5.
Hellebust T, Heikkila I, Frykholm G, Levernes S, Johannessen D, Bjerke H, et al.
J Radiother Pract
. 2014 Mar;
13(1):35-44.
PMID: 24611030
Background And Purpose: In radiotherapy (RT), there are high requirements for quality assurance (QA) in all the steps of the process. Development of QA systems are demanding in terms of...
6.
Strand T, Brunsvig P, Johannessen D, Sundstrom S, Wang M, Hornslien K, et al.
Int J Radiat Oncol Biol Phys
. 2010 May;
80(1):133-41.
PMID: 20452137
Purpose: The efficacy of curative irradiation in the treatment of non-small-cell lung cancer patients is considered limited. The purpose of this study was to evaluate long-term survival in a population-based...
7.
Paul Muren L, Wasbo E, Helle S, Hysing L, Karlsdottir A, Odland O, et al.
Int J Radiat Oncol Biol Phys
. 2008 Feb;
71(4):1034-41.
PMID: 18249502
Purpose: We present planning and early clinical outcomes of a study of intensity-modulated radiotherapy (IMRT) for locally advanced prostate cancer. Methods And Materials: A total of 43 patients initially treated...
8.
Sundstrom S, Bremnes R, Aasebo U, Aamdal S, Hatlevoll R, Brunsvig P, et al.
J Clin Oncol
. 2004 Mar;
22(5):801-10.
PMID: 14990635
Purpose: To investigate whether the effect of hypofractionated thoracic radiotherapy (TRT) is comparable to more standard fractionated radiotherapy (RT) in advanced non-small-cell lung cancer (NSCLC). Patients And Methods: A total...